SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a therapeutic technology company focused on
unmet needs in global health and biodefense, announced today that
validation has completed and the opposition period expired for
European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS
FOR QUANTIFYING EXOSOMES." The patent was validated in Germany, France, Great
Britain, and Spain.
In recent years, exosomes have emerged as a significant
diagnostic and therapeutic tool for a wide range of disease
conditions, including cancer, tuberculosis, Alzheimer's, and
chronic traumatic encephalopathy (CTE). This validated European
Patent is an important addition to Aethlon Medical's patent
portfolio as it protects methods for quantifying any type of
exosome captured by lectin affinity using Galanthus nivalis lectin
(GNA), Narcissus pseudonarcissus lectin (NPA), Allium sativum
lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin
(SNA), Maackia amurensis lectin (MAL) or concanavalin A. The patent
has claims encompassing methods of quantifying exosomes associated
with CTE, Alzheimer's, cancer, or any other disease condition by
contacting a sample having any type of exosome with GNA, NPA, ASA,
LCH, SNA, MAL, or conconavalin A immobilized on a substrate,
contacting the bound exosomes with a detectable exosome-binding
agent, and measuring a signal from the bound detectable
exosome-binding agent, thereby quantifying the bound exosomes. This
European patent further expands Aethlon Medical's patent position
on diagnostic and therapeutic approaches in the field of exosome
biology.
About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet needs in global
health and biodefense. The Aethlon Hemopurifier® is a
first-in-class therapeutic device designed to address
life-threatening viral infections. The United States Food and
Drug Administration (FDA) has designated the Hemopurifier® as a
Breakthrough Device related to the treatment of life-threatening
viruses that are not addressed with approved therapies.
In collaboration with leading government and non-government
research institutes, Aethlon has validated the ability of the
Hemopurifier® to capture a broad-spectrum of pandemic influenza
viruses, mosquito-borne viruses and deadly hemorrhagic
viruses. Based on its use to treat Ebola virus, the
Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven
Most Remarkable Advances in Healthcare," by TIME Magazine.
Aethlon is also investigating the potential therapeutic use of
the Hemopurifier® to reduce the presence of tumor-derived exosomes,
which contribute to immune-suppression and the spread of metastasis
in cancer patients. Additionally, Aethlon is the majority
owner of Exosome Sciences, Inc. (ESI), which is focused on the
discovery of exosomal biomarkers to diagnose and monitor cancer and
neurological disorders, including Alzheimer's disease (AD) and
Chronic Traumatic Encephalopathy (CTE). Additional
information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com. You can also connect with us on
Twitter, LinkedIn, Facebook and Google+.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," or similar expressions
constitute forward-looking statements. Forward-looking statement
includes statements relating to the public offering and the
satisfaction of closing conditions relating to the public offering,
as well as general economic and market factors. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. Factors that
may contribute to such differences include, without limitation, the
Company's ability to maintain its listing on the Nasdaq Capital
Market, or any other national securities exchange, that the Company
or its subsidiary will not be able to commercialize its products,
that the FDA will not approve the initiation or continuation of the
Company's clinical programs or provide market clearance of the
Company's products, the Company's ability to raise capital when
needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products
either internally or through outside companies, the impact of
government regulations, patent protection on the Company's
proprietary technology, the ability of the Company to meet the
milestones contemplated in its contract with DARPA, product
liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. The foregoing list of
risks and uncertainties is illustrative, but is not exhaustive.
Additional factors that could cause results to differ materially
from those anticipated in forward-looking statements can be found
under the caption "Risk Factors" in the Company's Annual Report on
Form 10-K for the year ended March 31, 2017, and in the
Company's other filings with the Securities and Exchange
Commission. Except as may be required by law, the Company does not
intend, nor does it undertake any duty, to update this information
to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com
Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com
View original
content:http://www.prnewswire.com/news-releases/aethlon-medical-announces-validation-completion-for-european-patent-protecting-methods-of-quantifying-exosomes-300586366.html
SOURCE Aethlon Medical, Inc.